Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 213

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 213
---
 by a reduction of $0.2 million in compensation expenses and the scientific operations were conducted with more consulting and fewer employees in the three-month period ended September 30, 2024, versus the three-month period ended September 30, 2023. The remaining $0.1 million increase in the three-month period ended September 30, 2024, over the three-month period ended September 30, 2023, was related to lab supplies and expenses, additional pre-clinical work and facilities rent escalation. The Company anticipates that its R&D expenses will significantly increase in the future as the Company increases headcount, compensation expense, and contracted services for preclinical and clinical development of its product candidates, as well as for manufacturing of product to be used in clinical development. Other Income Other income was $0.2 million for the three-month period ended September 30, 2024 and 2023. The immaterial change was related to higher interest income and slightly lower gain from revaluation of liabilities in the three-month period ended September 30, 2024, versus the three-month period ended September 30, 2023. 134 Results of Operations for the nine-months ended September 30, 2024 and 2023 The Results of Operations for the nine-month period ended September 30, 2024 are pro formaas the period presented in the following table and discussion includes the Predecessor for the period from January 1, 2024 through February 13, 2024 and the Company for the period from February 14, 2024 through September 30, 2024. This pro forma period from January 1, 2024 to September 30, 2024 does not include the Merger transactions that occurred on-the-line. CERO THERAPEUTICS HOLDINGS, INC. Condensed Consolidated STATEMENTS OF OPERATIONS (Unaudited)

| Operating expenses:                             |     | For the nine months ended         
 September 30,                     
 2024                              
 (Pro                              
 forma, Predecessor and Successor) |             |   |     | 2023          
 (Predecessor) |            |   |     | Difference |            |   |
|:------------------------------------------------|:----|:----------------------------------|------------:|:--|:----|:--------------|-----------:|:--|:----|:-----------|-----------:|:--|
| Research and development                        |     | $                                 |   6